Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Qua, V. Palmero, R. Sulica (New York, United States Of America). Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 942

Member's Comments

No comment yet.

Related content which might interest you: Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Inhaled iloprost improves hemodynamics at exercise in primary and secondary precapillary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term improvement of pulmonary haemodynamics and exercise capacity in patients with pulmonary hypertension and hypoventilation following NIPPV and influence of NIPPV adherence Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Hemodynamic correlates of exercise capacity in patients with pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 17s Year: 2005 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005